Edition:
United Kingdom

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

1.61USD
15 Dec 2017
Change (% chg)

$-0.09 (-5.29%)
Prev Close
$1.70
Open
$1.69
Day's High
$1.70
Day's Low
$1.60
Volume
8,339
Avg. Vol
21,711
52-wk High
$6.50
52-wk Low
$1.35

Select another date:

Tue, Dec 12 2017

BRIEF-Soleno Therapeutics Announces $15 Million Private Placement

* SOLENO THERAPEUTICS ANNOUNCES $15 MILLION PRIVATE PLACEMENT

BRIEF-Soleno Therapeutics Announces Joint Venture Agreement For Commercialization Of Cosense Monitoring Technology

* SOLENO THERAPEUTICS ANNOUNCES JOINT VENTURE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF COSENSE MONITORING TECHNOLOGY

BRIEF-Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations

* Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results

BRIEF-Soleno Therapeutics regains compliance with Nasdaq listing requirements

* Soleno Therapeutics regains compliance with nasdaq listing requirements Source text for Eikon: Further company coverage:

BRIEF-Soleno Therapeutics announces 1-for-5 reverse stock split

* Soleno Therapeutics - reverse stock split of all of co's outstanding common shares at an exchange ratio of 1-for-5 will take effect on October 6, 2017 Source text for Eikon: Further company coverage:

BRIEF-Soleno Therapeutics receives scientific advice from EMA

* Soleno Therapeutics says ‍has received scientific advice from CHMP of European Medicines Agency regarding diazoxide choline controlled-release for treatment of prader-willi syndrome

BRIEF-Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome

* Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome

BRIEF-Soleno Therapeutics issues new U.S. patent for DCCR in treatment of Prader-Willi syndrome

* Soleno Therapeutics announces issuance of new U.S. patent for DCCR in treatment of Prader-Willi syndrome

BRIEF-Soleno Therapeutics reports Q2 loss/share of $0.07

* Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results

BRIEF-Soleno Therapeutics Q2 loss per share $0.07

* Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results

Select another date: